Swiss Prospective Cohort Study on Well-Being and Health of Transgender and Gender Diverse Individuals Receiving Gender-Affirming Therapies

What this Trial Is About

Researchers are studying the well-being and health of transgender and gender-diverse TGD individuals aged 16 and older in Switzerland who are undergoing gender-affirming therapies. This observational study aims to understand the key factors that affect their health outcomes and quality of life across different stages of medical transition, including those who have discontinued or detransitioned. The study compares health outcomes among subgroups to examine the effects of gender-affirming therapies. Participants are grouped based on their stage in the gender-affirming process those before starting gender-affirming hormone therapy GAHT, those currently on GAHT, and those undergoing gender-affirming surgery GAS. Group A has assessments at baseline and follow-up visits typically every three months in the first year, then every six months in the second year, and yearly thereafter. Group B participates in yearly assessments as part of long-term routine follow-up. Group C includes additional preoperative and postoperative assessments around surgery, including microbiome analyses if genital surgery is involved. Participants complete electronic questionnaires on gender congruence, quality of life, and mental health, and provide biological samples such as blood, urine, stool, and skin swabs. Clinical evaluations related to endocrinology, fertility, dermatology, and urology are conducted as part of routine care. Researchers measure outcomes including gender congruence using validated scales at multiple time points up to 20 years. The study involves both digital and in-person data collection methods to monitor health and well-being over time.

Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study